Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
about
Feedback Regulation of Kinase Signaling Pathways by AREs and GREsA muscle stem cell for every muscle: variability of satellite cell biology among different muscle groupsThe importance of CELF control: molecular and biological roles of the CUG-BP, Elav-like family of RNA-binding proteinsRNA-binding proteins and gene regulation in myogenesisThe RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicingNew function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeatsMuscleblind-like 1 is required for normal heart valve development in vivo.Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.Recent progress in histochemistry and cell biology.MBNL proteins and their target RNAs, interaction and splicing regulation.C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patientsAntisense therapy in neurologySmaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.Small molecules that target the toxic RNA in myotonic dystrophy type 2.Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2.RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2Identification of Targets of CUG-BP, Elav-Like Family Member 1 (CELF1) Regulation in Embryonic Heart Muscle.CUG-BP1 regulates RyR1 ASI alternative splicing in skeletal muscle atrophy.CELFish ways to modulate mRNA decay.CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments.Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.Molecular mechanisms of muscle atrophy in myotonic dystrophies.RNA binding proteins in the regulation of heart development.GSK3β is a new therapeutic target for myotonic dystrophy type 1.Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer.Positive muscle phenomena--diagnosis, pathogenesis and associated disorders.The role of CUGBP1 in age-dependent changes of liver functions.Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts.Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress.(CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis.Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence.RNA-binding proteins regulate the expression of the immune activating ligand MICB.Nuclear ribonucleoprotein-containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2.Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.Alternative splicing alterations of Ca2+ handling genes are associated with Ca2+ signal dysregulation in myotonic dystrophy type 1 (DM1) and type 2 (DM2) myotubes.Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.RNA processing is altered in skeletal muscle nuclei of patients affected by myotonic dystrophy
P2860
Q26773059-FE9BE831-C9E7-4429-A786-75E44D1AD96CQ26779289-A789EFA4-5DB5-47FD-A53E-A3D9A0E9D0C5Q26823119-D1BACF07-3034-4C27-B411-AC085CFF67FCQ26866134-4A06CCF0-030D-48E8-9F33-838E73CCACA1Q30424920-E7EEA1D6-7599-421B-85AD-DEA3B89E5830Q30427374-F83B6201-A427-4311-B63C-426F2ED28B31Q30668792-CE51CA6E-90DE-4EAD-B0C6-65AF3CCD40A3Q30854929-7AB8E5EF-F156-4174-B60A-3AD450C5FD9BQ34172616-97EF4C8C-28F7-47D9-B28A-AEE3F627215DQ34248811-00D5CFEA-0A60-44A3-BDB8-5B907A614607Q34599648-CE15061B-604F-4F07-A848-D5CB8039F269Q34608717-C73645E2-590A-4FE2-988A-3C33247DF7FEQ34699771-059D54BF-EF58-4AD6-94BB-425B109018FCQ35061734-E3259F27-2C64-452D-9E1E-84B7E90E29D7Q35078193-A06993FD-0EA1-4462-85D4-0C3037B8ED3DQ35474587-EF141105-6BB1-4ADC-918C-B14374AF1938Q35920624-DABD1563-7DCA-49AF-B224-5B4F41FEA51DQ36245773-3E6218FE-0225-4311-8559-E23C2CAAFF3BQ36807677-F192B600-FA8F-40F2-8287-8BBA710AF3ADQ36831893-6F8F0C8B-4640-4BDA-829E-CD045B3F8623Q36879671-676AB0D1-A878-4946-9092-1D9DC9A64AF5Q36944554-3F145593-D118-4FDD-9600-CC794EF8F8EFQ37138514-F86C2A24-224F-4C39-8C35-04D16D2AA825Q37245183-BC358905-ADC7-4F6E-8369-43467964690FQ37590296-6D1ABC31-D6C7-4F34-9278-FB69386F991AQ37855730-A7730EBA-A136-47D4-885D-8754F727161DQ37978120-B9C336D7-C4CE-49E6-BEA6-7F754684A721Q37996811-824BA84E-01BE-4F14-8F7D-551FABF79496Q38177257-C736253E-9C02-4978-8C8D-5D22DC7EC9F3Q38209927-9F582B88-F222-4875-9942-893FE9C1448CQ38330480-C0F6DF3C-D684-43B4-AADC-03DA85F83CBEQ38432204-212EB1E3-FB67-4BDE-B171-9E9684E92FBCQ38721747-4CD5BEC1-5AED-4126-97C6-97C39F70F0CBQ38852912-83C9A28F-06EE-49C1-BFCC-43629791FE51Q40919209-6A7A55BF-98B6-4F25-A16B-334DD76A39DEQ47303392-EA3708D5-FEA6-42F8-9DA5-1ED46A992DFAQ47332454-E568B65C-C1C1-4870-BB87-3C79E75365C8Q47929916-370CB598-38A6-49A2-A78D-F94E0144A564Q50755664-5CA51F1B-BE10-482F-9F7A-C46F6EB3FCD5Q57085790-9BE145F7-CB8F-4D01-8E3F-88255A304085
P2860
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@ast
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@en
type
label
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@ast
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@en
prefLabel
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@ast
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.
@en
P2860
P1433
P1476
Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms
@en
P2093
Lubov Timchenko
P2860
P356
10.2174/138920210790886844
P577
2010-04-01T00:00:00Z